Treatment of children with refractory anemia: The Japanese Childhood MDS Study Group trial (MDS99)
Authors:
- Daisuke HasegawaDHDaisuke Hasegawa
- Atsushi ManabeAMAtsushi Manabe
- Hiroshi YagasakiHYHiroshi Yagasaki
- Akira KikuchiAKAkira Kikuchi
- Akira OharaAOAkira Ohara
- Seiji KojimaSKSeiji Kojima
- Tatsutoshi NakahataTNTatsutoshi Nakahata
- on behalf of Japanese Childhood MDS Study GroupOGon behalf of Japanese Childhood MDS Study Group
- 1 December 2009
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (6) , 1011-1015
Abstract
BackgroundAlthough hematopoietic stem cell transplantation (HSCT) is offered as a curative therapy for pediatric myelodysplastic syndrome (MDS), it may cause severe complications and mortality. Several reports have shown the efficacy of immunosuppressive therapy (IST) in adult patients with refractory anemia (RA), but its safety and efficacy remains to be fully elucidated in childhood RA.ProcedureEleven children diagnosed with RA and enrolled on a prospective multicenter trial conducted by the Japanese Childhood MDS Study Group were eligible for analysis. If patients showed transfusion dependent or suffered from infection due to neutropenia, they received IST consisting of antithymocyte globulin (ATG), cyclosporine (CyA), and methylprednisolone (mPSL).ResultsEight children received IST, 2 received only supportive therapy, and one underwent HSCT without IST. Five (63%) of eight children who received IST showed hematological response. Of note, one patient showed the disappearance of monosomy 7 after IST. Responders were significantly younger than non‐responders (29 months vs. 140 months; P = 0.03). No severe adverse events related to IST were reported in this study. Of 6 children with chromosomal abnormalities who received IST, four showed hematological response. The probability of failure‐free and overall survival at 5 years was 63 ± 17% and 90 ± 9% respectively.ConclusionIST is likely to be a safe and effective modality for childhood RA. Pediatr Blood Cancer 2009;53:1011–1015.Keywords
This publication has 21 references indexed in Scilit:
- T-cell receptor Vβ CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemiaLeukemia, 2008
- Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndromeBlood, 2005
- Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7Blood, 2003
- A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseasesLeukemia, 2003
- Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasiaCancer, 2002
- HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromeBlood, 2002
- Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in JapanLeukemia, 2001
- Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 PatientsBlood, 1999
- Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrowBritish Journal of Haematology, 1998
- Antithymocyte globulin for patients with myelodysplastic syndromeBritish Journal of Haematology, 1997